Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$3.83
-3.2%		$5.22
$2.49
▼
$7.18
$725.14M1.212.91 million shs1.11 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$18.20
-1.7%		$24.50
$11.92
▼
$27.31
$3.39B1.082.20 million shs1.64 million shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$12.35
-5.9%		$13.42
$7.05
▼
$17.15
$360.21M0.93201,008 shs85,163 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
+0.25%-18.89%-25.33%-12.61%+63.22%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+1.70%-23.72%-27.94%+2.49%+40.84%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
+1.23%-6.82%-0.30%+8.70%+58.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$3.83
-3.2%		$5.22
$2.49
▼
$7.18
$725.14M1.212.91 million shs1.11 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$18.20
-1.7%		$24.50
$11.92
▼
$27.31
$3.39B1.082.20 million shs1.64 million shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$12.35
-5.9%		$13.42
$7.05
▼
$17.15
$360.21M0.93201,008 shs85,163 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
+0.25%-18.89%-25.33%-12.61%+63.22%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+1.70%-23.72%-27.94%+2.49%+40.84%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
+1.23%-6.82%-0.30%+8.70%+58.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annexon, Inc. stock logo
ANNX
Annexon
2.40
Hold$15.14295.89% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.81
Moderate Buy$32.1776.73% Upside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.67
Moderate Buy$21.0070.03% Upside

Current Analyst Ratings Breakdown

Latest DYN, ANNX, and ENTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$45.00 ➝ $36.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$30.00 ➝ $26.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$35.00 ➝ $30.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Underweight$17.00 ➝ $10.00
9/8/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$37.00
9/1/2026
Annexon, Inc. stock logo
ANNX
Annexon
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$10.00 ➝ $14.00
8/17/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
8/13/2026
Annexon, Inc. stock logo
ANNX
Annexon
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
7/31/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$47.00 ➝ $45.00
7/30/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$30.00 ➝ $35.00
7/23/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight
(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$1.42 per shareN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$65.32M5.51N/AN/A$3.03 per share4.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.16N/AN/AN/AN/A-106.15%-79.82%11/9/2026 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$81.89M-$2.41N/AN/AN/A-96.89%-61.84%-20.70%11/16/2026 (Estimated)

Latest DYN, ANNX, and ENTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.2388-$0.28-$0.0412-$0.28$6.50 millionN/A
8/10/2026Q3 2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$0.5095-$0.67-$0.1605-$0.67$16.76 million$14.36 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annexon, Inc. stock logo
ANNX
Annexon
N/A
5.53
5.53
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
3.76
3.76

Institutional Ownership

CompanyInstitutional Ownership
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%

Insider Ownership

CompanyInsider Ownership
Annexon, Inc. stock logo
ANNX
Annexon
10.31%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
11.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annexon, Inc. stock logo
ANNX
Annexon
92189.58 million170.03 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
258186.75 million169.08 millionOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
12029.12 million25.78 millionOptionable

Recent News About These Companies

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Crosses Below 200 Day Moving Average - Here's What Happened
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-enanta-pharmaceuticals-nasdaq-enta-stock-price-crosses-below-200-day-moving-average-heres-what-happened-2026-09-09/
BlackRock Inc. Purchases New Shares in Enanta Pharmaceuticals, Inc. $ENTA
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-purchases-new-shares-in-enanta-pharmaceuticals-inc-enta-2026-09-01/
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of "Moderate Buy" from Brokerages
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-enanta-pharmaceuticals-inc-nasdaq-enta-receives-average-rating-of-moderate-buy-from-brokerages-2026-08-31/
Connor Clark & Lunn Investment Management Ltd. Invests $2.23 Million in Enanta Pharmaceuticals, Inc. $ENTA
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-connor-clark-lunn-investment-management-ltd-invests-223-million-in-enanta-pharmaceuticals-inc-enta-2026-08-30/
3,654,920 Shares in Enanta Pharmaceuticals, Inc. $ENTA Purchased by Jupiter Topco LLC
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-3654920-shares-in-enanta-pharmaceuticals-inc-enta-purchased-by-jupiter-topco-llc-2026-08-28/
1,344,510 Shares in Enanta Pharmaceuticals, Inc. $ENTA Bought by ADAR1 Capital Management LLC
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-1344510-shares-in-enanta-pharmaceuticals-inc-enta-bought-by-adar1-capital-management-llc-2026-08-26/
Spruce Street Capital LP Acquires Shares of 1,088,731 Enanta Pharmaceuticals, Inc. $ENTA
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-spruce-street-capital-lp-acquires-shares-of-1088731-enanta-pharmaceuticals-inc-enta-2026-08-25/
Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded to "Sell" Rating by Wall Street Zen
August 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/enanta-pharmaceuticals-nasdaqenta-downgraded-to-sell-rating-by-wall-street-zen-2026-08-22/
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Passes Above 200 Day Moving Average - Here's What Happened
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/enanta-pharmaceuticals-nasdaqenta-stock-passes-above-200-day-moving-average-heres-what-happened-2026-08-21/
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972293/enanta-pharmaceuticals-enta-reports-q3-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2972293
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
August 10, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260810427925/en/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-ended-june-30-2026/
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
June 24, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2942017/enanta-pharmaceuticals-enta-moves-5-2-higher-will-this-strength-last?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2942017
EC approves label expansion for Enanta’s Maviret in acute HCV infection
June 24, 2026  |  thepharmaletter.comT
Enanta Faces Patent Setback in Paxlovid Litigation
June 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/enanta-faces-patent-setback-in-paxlovid-litigation?utm_source=marketbeat.com&utm_medium=referral
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
May 11, 2026  |  pharmiweb.comP
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
May 11, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2919302/enanta-pharmaceuticals-enta-reports-q2-loss-lags-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2919302
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
May 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2916747/enanta-pharmaceuticals-enta-moves-5-3-higher-will-this-strength-last?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2916747
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
April 13, 2026  |  pharmiweb.comP
Enanta Pharmaceuticals Announces Public Stock Offering
April 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/enanta-pharmaceuticals-announces-public-stock-offering/ar-AA1NHvEM
Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory ...
April 7, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68135370-enanta-pharmaceuticals-inc-enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-n-protein-inhibitor-in-development-for-the-004.htm
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID ...
April 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/enanta-pharmaceuticals-present-data-zelicapavir-110000061.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
A rubber stamp reading "Dividends" rests beside a stamped document, stacked coins, and US currency.
3 Closed-End Funds to Maximize Dividend Payments
By Nathan Reiff | August 23, 2026
Autonomous mobile robots carrying storage bins move through an automated factory production line with illuminated blue accents.
3 Robotics Stocks Under $10: Value, Momentum, or Bet?
By Chris Markoch | August 17, 2026
Desk with a monitor showing an upward stock price chart, printed financial reports, and a bronze bull statue.
3 Earnings Season Winners That Analysts Can't Stop Upgrading
By Dan Schmidt | September 7, 2026
Annexon stock logo

Annexon NASDAQ:ANNX

$3.82 -0.13 (-3.16%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$18.20 -0.32 (-1.72%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$12.35 -0.77 (-5.86%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas